Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines - PubMed (original) (raw)

Review

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines

J Dutcher et al. Med Oncol. 2001.

Abstract

The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regarding the efficacy of the high-dose interleukin-2 (IL2)/lymphokine-activated killer cell (LAK cell) regimen piloted at the NCI in the treatment of renal cell cancer. Since those initial studies, the CWG has conducted a series of clinical trials, often with correlative immunologic investigations, to evaluate combination immunotherapy in attempts to enhance the efficacy of IL-2 or to reduce toxicity. Subsequently, the CWG conducted trials to demonstrate the activity of lower-dose outpatient combination cytokine regimens to help determine their role in the armamentarium of treatment for metastatic renal cell cancer. This has culminated in a phase III randomized trial comparing the activity of high-dose IL-2 with the activity of outpatient IL-2 plus interferon-alpha. The CWG also has honed the management of both high-dose IL-2 and outpatient IL-2 regimens to make these safer in the hands of experienced clinicians. In addition, the CWG has produced a series of carefully conducted clinical trials of new cytokines, again attempting to define their clinical efficacy as anticancer agents. These include studies of IL-4, IL-6, and IL-12. Currently, the CWG is conducting studies with new approaches to IL-2 therapy, as well as planning trials with new agents for treatment of renal cell cancer. This review describes these efforts conducted over the past 15 yr.

PubMed Disclaimer

Cited by

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.
Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. Dutcher JP, et al. J Immunother Cancer. 2014 Sep 16;2(1):26. doi: 10.1186/s40425-014-0026-0. J Immunother Cancer. 2014. PMID: 31546315 Free PMC article. Review.
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial.
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Canter D, Kutikov A, Golovine K, Makhov P, Simhan J, Uzzo RG, Kolenko VM. Canter D, et al. Can J Urol. 2011 Aug;18(4):5819-25. Can J Urol. 2011. PMID: 21854714 Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP. Wrangle JM, et al. J Interferon Cytokine Res. 2018 Feb;38(2):45-68. doi: 10.1089/jir.2017.0101. J Interferon Cytokine Res. 2018. PMID: 29443657 Free PMC article. Review.
Mathematical model for IL-2-based cancer immunotherapy.
Dixon M, Phan TA, Dallon JC, Tian JP. Dixon M, et al. Math Biosci. 2024 Jun;372:109187. doi: 10.1016/j.mbs.2024.109187. Epub 2024 Apr 2. Math Biosci. 2024. PMID: 38575057 Free PMC article.

References

1. Dermatol Clin. 2000 Jan;18(1):169-75, x - PubMed
1. Cancer Res. 1991 Oct 15;51(20):5687-93 - PubMed
1. J Exp Med. 1990 Mar 1;171(3):629-36 - PubMed
1. Blood. 1997 Oct 1;90(7):2541-8 - PubMed
1. J Clin Oncol. 1992 Nov;10(11):1802-9 - PubMed

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines - PubMed (original) (raw)